Log in

ACET Adicet Bio, Inc. NASDAQ · United States

Adicet Bio (ACET) news

Latest Adicet Bio news

  1. Distress

    Adicet Bio announces workforce reduction of about 30% and ends ADI-270 program

    Adicet's board approved a cut of about 30% of its workforce on July 22, 2025 and ended its ADI-270 cancer program. The company expects about $2.3 million in charges and a cash runway into the fourth quarter of 2026, after a $117.1 million net loss in 2024.

Adicet Bio annual financials

LineFY2025FY2024
Research and development$99.1 million$99.3 million
Net income (loss)-$116.8 million-$117.1 million
Cash from operations-$95.2 million-$92.4 million
Cash and equivalents$38.9 million$56.5 million

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $33.1 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about Adicet Bio

What is the ticker symbol of Adicet Bio?

Adicet Bio, Inc. trades under the ticker ACET on NASDAQ.

Where is Adicet Bio listed?

Adicet Bio, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:1IJ; LS:A41X5V; LSE:0HX7; LSX:A41X5V.

What is the SEC CIK of Adicet Bio?

The SEC Central Index Key (CIK) for Adicet Bio, Inc. is 1720580. Its filings are on SEC EDGAR.

How many shares does Adicet Bio have outstanding?

9,361,490 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-05.

Which country or territory is Adicet Bio listed under?

Our directory records Adicet Bio, Inc. under United States.

What does Adicet Bio do?

Our directory classifies Adicet Bio, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Adicet Bio?

The ISIN recorded for Adicet Bio, Inc. is US0070022076.

Does aibio.space cover Adicet Bio?

aibio.space lists Adicet Bio, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Adicet Bio incorporated?

SEC records list its state or country of incorporation as DE.

Is Adicet Bio profitable?

Adicet Bio, Inc. reported a net loss of $116.8 million for the fiscal year ended Dec 31, 2025, and used $95.2 million of cash in operations, per its annual report to the SEC.

How much does Adicet Bio spend on research and development?

$99.1 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does Adicet Bio have?

$33.1 million in cash at Jun 30, 2026, per its 10-Q.

What is the latest Adicet Bio (ACET) stock news?

Our latest story on Adicet Bio, dated Oct 7, 2025: "Adicet Bio gets until April 6, 2026 to meet Nasdaq bid price rule, moves listing". Nasdaq granted Adicet Bio an additional 180 calendar days. The stock moves from the Nasdaq Global Market to the Nasdaq Capital Market on October 9, 2025. Source.

How long will Adicet Bio's cash last?

From our story of Jul 23, 2025: The company expects about $2.3 million in charges and a cash runway into the fourth quarter of 2026, after a $117.1 million net loss in 2024. Source.

Is Adicet Bio in financial distress?

Our latest distress story, dated Jul 23, 2025: "Adicet Bio announces workforce reduction of about 30% and ends ADI-270 program". Adicet's board approved a cut of about 30% of its workforce on July 22, 2025 and ended its ADI-270 cancer program. The company expects about $2.3 million in charges and a cash runway into the fourth quarter of 2026, after a $117.1 million net loss in 2024. Source.

Investor discussion: Adicet Bio

Members talk about Adicet Bio (ACET). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Adicet Bio, newest first. Each line links the filing it comes from.

  1. Financings

    Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,9.01). Source

  2. Financings

    Reported a financing. SEC Form 8-K (Items 7.01,8.01,9.01). Source

  3. Listings

    Reported a reverse stock split. SEC Form 8-K (Items 5.03,8.01,9.01). Source

  4. Listings

    Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source

  5. Listings

    Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source

  6. Listings

    Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source

  7. Financings

    Reported a financing. SEC Form 424B5. Source

  8. Listings

    Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source

  9. Distress

    Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,8.01,9.01). Source

  10. Listings

    Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source

  11. Financings

    Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source

  12. Financings

    Set up an at-the-market program to sell shares over time. SEC Form S-3. Source

  13. Distress

    Reported the end of a material agreement. SEC Form 8-K (Items 1.02). Source

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:ACET on TradingView.

SEC filings and registration

SEC name
Adicet Bio, Inc.
CIK
1720580
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
ACET (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 26
Filer category
Non-accelerated filer<br>Smaller reporting company
Business address
131 DARTMOUTH STREET, BOSTON, MA, 02116
Phone
617-482-2333
Shares outstanding
9,361,490 as of 2026-08-03 (10-Q filed 2026-08-05)
Former names
resTORbio, Inc.

Recent filings (8-K and 6-K are the company's own announcements)

  • 8-K filed 2026-09-28
  • 8-K filed 2026-09-08
  • 8-K filed 2026-09-01
  • 10-Q filed 2026-08-05
  • 8-K filed 2026-08-05
  • 8-K filed 2026-06-18
  • 10-Q filed 2026-05-13
  • 8-K filed 2026-05-13

Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

Listing details

Adicet Bio, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ACET, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Adicet Bio, Inc.
Ticker
ACET
Listing
NASDAQ
Country or territory
United States
Business scope
Pharmaceuticals: Major
ISIN
US0070022076
Other listed symbols
GETTEX:1IJ; LS:A41X5V; LSE:0HX7; LSX:A41X5V
Last quote in directory
2026-10-21
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.